Details for Patent: 10,206,813

Which drugs does patent 10,206,813 protect, and when does it expire?

Patent 10,206,813 protects IDOSE TR and is included in one NDA.

This patent has fifty-two patent family members in seven countries.

Summary for Patent: 10,206,813

Patent landscape, scope, and claims:

Title:	Implants with controlled drug delivery features and methods of using same
Abstract:	Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Inventor(s):	Haffner David S., Burns Thomas W., Heitzmann Harold A., Curry Kenneth M.
Assignee:	Dose Medical Corporation
Application Number:	US14201470
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,206,813

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes	10,206,813		Y

International Family Members for US Patent 10,206,813

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010249683
Australia	2014237278
Australia	2014348667
Australia	2015230797